Audrey Sternberg

Articles

Oral Regimen for Paclitaxel Administration May Become Available in Breast Cancer

December 13th 2019

The addition of encequidar (HM30181A) to oral paclitaxel is the first oral taxane regimen to result in an improvement in overall response rates as compared with an intravenous administration of paclitaxel in patients with metastatic breast cancer.

Benefit in pCR Rates Are Achieved With Pembrolizumab in Early TNBC

December 12th 2019

Patients with triple-negative breast cancer have greater rates of pathologic complete responses when pembrolizumab is added to neoadjuvant and adjuvant chemotherapy. Furthermore, these benefits are observed across patient subgroups, most notably in those patients with stage III and/or node-positive disease.

Extramedullary Multiple Myeloma Responds to Dual-Targeting CAR T-Cell Therapy

December 7th 2019

Chimeric antigen receptor T-cell therapy targeting both BCMA and CD38 induced an objective response in >90% of patients with multiple myeloma who had been treated with at least 3 prior therapies and whose disease had spread outside of the bone marrow.

Efforts Continue to Perfect PARPi Use in Ovarian Cancer

November 8th 2019

As PARP inhibitors have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.

Expert Explains Treatment Considerations in Newly Diagnosed Follicular Lymphoma

November 7th 2019

Given that a watch-and-wait approach is a viable option, clinicians must carefully consider disease characteristics when selecting a treatment strategy in newly diagnosed follicular lymphoma.

Clinical Utility of Tumor Mutational Burden Remains in Flux

May 20th 2019

Although study findings have identified tumor mutational burden as an important factor in responses to cancer therapy, establishing a definition for expression of this biomarker and harmonizing assays to measure it have proved challenging.

Lower-Dose Tamoxifen Reduces Recurrence Risk, Toxicity Incidence in Breast Cancer

December 7th 2018

The use of low-dose tamoxifen was shown to significantly reduce the risk of new and recurrent disease following surgery in women diagnosed with breast intraepithelial neoplasia but it did not cause more serious adverse events compared with placebo.

Hispanics Are at Highest Risk of Neurotoxicity From Chemotherapy for ALL

November 12th 2018

Ethnic differences in the prevalence of neurotoxicity from methotrexate therapy may help explain why minority patients, specifically Hispanics, experience disparities in treatment outcomes for pediatric acute lymphoblastic leukemia.

Tumor Treating Fields Show Promise in Ovarian Cancer

August 7th 2018

In combination with weekly paclitaxel, tumor treating fields, an antimitotic therapy that delivers continuous low-intensity electrical fields to the tumor region, has been found safe in platinum-resistant ovarian cancer.